Kaempferol 3-O-β-D-galactopyranoside
Based on 1 publication(s) in Google Scholar
Kaempferol 3-O-β-D-galactopyranoside (Trifolin) is an orally active flavonoid derivative that can be found in the aerial parts of Consolida oliverana. Kaempferol 3-O-β-D-galactopyranoside exhibits antitumor and cardioprotective effects.
For research use only. We do not sell to patients.
- Purity : 99.58%
- CAS No.: 23627-87-4
- Formula: C21H20O11
- Molecular Weight:448.38
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Kaempferol 3-O-β-D-galactopyranoside
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.2 | IC50 |
161.32 μM
Compound: 3
|
Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
|
[PMID: 19489596] |
| MDCK | CC50 |
143.3 μg/mL
Compound: 10
|
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | CC50 |
215 μg/mL
Compound: 10
|
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | IC50 |
>300 μg/mL
Compound: 10
|
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | IC50 |
143.3 μg/mL
Compound: 10
|
Cytotoxicity against MDCK cells
Cytotoxicity against MDCK cells
|
[PMID: 15104496] |
| MDCK | IC50 |
53.8 μg/mL
Compound: 10
|
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
| MDCK | IC50 |
71.7 μg/mL
Compound: 10
|
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect
|
[PMID: 15104496] |
In Vitro
Kaempferol 3-O-β-D-galactopyranoside (12.5–50 μM, 24-48 h) inhibits the proliferation of NCI-H460 cells in a dose-dependent manner[2]. Kaempferol 3-O-β-D-galactopyranoside (12.5–50 μM, 48 h) increases the Sub-G1 phase cell population and induces apoptosis in NCI-H460 cells[2]. Kaempferol 3-O-β-D-galactopyranoside (12.5–50 μM, 48 h) modulates intrinsic and extrinsic apoptosis signaling pathways and induces apoptosis in NCI-H460 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H460 human non-small cell lung cancer cells
-
Concentration:12.5–50 μM
-
Incubation Time:24 h and 48 h
-
Result:Decreased cell viability to less than 50% at 50 μM after 48 h; Showed significant cytotoxicity only at 50 μM after 24 h.
-
Cell Line:NCI-H460 human non-small cell lung cancer cells
-
Concentration:12.5–50 μM
-
Incubation Time:48 h
-
Result:Increased Sub-G1 phase cell population, decreased G1 phase cell population, no significant change in G2/M phase.
-
Cell Line:NCI-H460 human non-small cell lung cancer cells
-
Concentration:12.5–50 μM
-
Incubation Time:24 h and 48 h
-
Result:Increased expression of Fas, FADD, and Bax; Decreased expression of Bcl-2 and cIAP-1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Angiotensin II (AngII) (HY-13948)-induced hypertensive cardiac injury C57BL/6 mice model[3]
-
Dosage:0.1, 1.0, and 10.0 mg/kg
-
Administration:Oral gavage (p.o.), once daily for 4 weeks
-
Result:Improved left ventricular ejection fraction (LVEF) and fractional shortening (LVFS). Alleviated inflammatory cell infiltration and pathological damage in cardiac tissue. Reduced cardiomyocyte apoptosis and regulated Bax, Bcl-2, and cleaved caspase-3 protein expression
Chemical Information
-
CAS No. 23627-87-4
-
Appearance Solid
-
Molecular Weight 448.38
-
Formula C21H20O11
-
Color Off-white to light yellow
-
SMILES
O=C1C2=C(O)C=C(O)C=C2OC(C3=CC=C(O)C=C3)=C1O[C@@H]4O[C@@H]([C@H](O)[C@H](O)[C@H]4O)CO
-
Synonyms
Trifolin
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (55.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.79 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.79 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. da Silva I, et al. Structure determination of monohydrated trifolin (kaempferol 3-O-β-D-galactopyranoside) from laboratory powder diffraction data. J Pharm Sci. 2011;100(4):1588-1593. [Content Brief]
[2]. Kim MJ, et al. Trifolin induces apoptosis via extrinsic and intrinsic pathways in the NCI-H460 human non-small cell lung-cancer cell line. Phytomedicine. 2016 Sep 15;23(10):998-1004. [Content Brief]
[3]. Zhang F, et al. Trifolin Attenuates Hypertension-Mediated Cardiac Injury by Inhibiting Cardiomyocyte Apoptosis: Mechanistic Insights and Therapeutic Potential. Eur J Pharmacol. 2024 Nov 9:177125. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2303 mL | 11.1513 mL | 22.3025 mL | 55.7563 mL |
| 5 mM | 0.4461 mL | 2.2303 mL | 4.4605 mL | 11.1513 mL | |
| 10 mM | 0.2230 mL | 1.1151 mL | 2.2303 mL | 5.5756 mL | |
| 15 mM | 0.1487 mL | 0.7434 mL | 1.4868 mL | 3.7171 mL | |
| 20 mM | 0.1115 mL | 0.5576 mL | 1.1151 mL | 2.7878 mL | |
| 25 mM | 0.0892 mL | 0.4461 mL | 0.8921 mL | 2.2303 mL | |
| 30 mM | 0.0743 mL | 0.3717 mL | 0.7434 mL | 1.8585 mL | |
| 40 mM | 0.0558 mL | 0.2788 mL | 0.5576 mL | 1.3939 mL | |
| 50 mM | 0.0446 mL | 0.2230 mL | 0.4461 mL | 1.1151 mL |
Kaempferol 3-O-β-D-galactopyranoside Related Classifications
HY-N6605 Related Classifications
Powered by Bioz